United StatesÚltimas notícias

Saul Martinez, Head of US Financials Research at HSBC, joins Bloomberg's Vonnie Quinn on "Bloomberg Brief" to discuss the upcoming earnings season for major US banks.

Atrium Therapeutics (NASDAQ:RNA) received FDA clearance for its Investigational New Drug application to begin a 37-participant Phase 1/2 clinical trial.

Apollo Global Management President Jim Zelter says private capital is stepping in to fill a financing gap left by governments whose balance sheets can no longer support large-scale industrial capital expenditure. "Government pocketbooks aren't as buoyant to be able to provide that," Zelter tells Bloomberg Television.

Xanadu (NASDAQ:XNDU) and Lockheed Martin (NYSE:LMT) announced a strategic collaboration to expand internal quantum programming training.

Summit Therapeutics (NASDAQ:SMMT) sold its investigational Phase III precision antibiotic ridinilazole to Biossil for up to $105 million.

JPMorgan Chase reported its highest quarterly profit ever as the second-quarter equities haul climbed 86% from a year earlier to $6.03 billion. Gerard Cassidy, head of US bank strategy and large-cap bank analyst at RBC examines the results on "Bloomberg Surveillance."

Fastenal (NASDAQ:FAST) reported second-quarter revenue of $2.39 billion and earnings per share of $0.33.

Bank of America (NYSE:BAC) reported second-quarter earnings per share of $1.21 on $31.6 billion in total revenue.

JPMorgan Chase (NYSE:JPM) reported a second-quarter earnings per share of $7.70 on $57.35 billion in total revenue.

Wells Fargo (NYSE:WFC) reported a 17% increase in net income to $6.41 billion for the second quarter.

Spero Therapeutics (NASDAQ:SPRO) licensed SP001 from Innovent Biologics in an agreement valued at approximately US$1.1 billion.

NextCure (NASDAQ:NXTC) agreed to merge with privately held Avere Therapeutics in an all-stock transaction supported by a concurrent $320 million private placement.